
Opinion|Videos|April 7, 2026
How ADCs Affect Sequencing Considerations in TNBC
Author(s)Neil Iyengar, MD, Kelsey Natsuhara, MD
Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss how the emergence of antibody-drug conjugates may impact sequencing considerations in triple-negative breast cancer.
Advertisement
Episodes in this series

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss how the integration of antibody-drug conjugates (ADCs) is influencing sequencing strategies in triple-negative breast cancer (TNBC). Iyengar examines the potential for sequential use of ADCs, including those targeting similar antigens such as TROP2. Natsuhara highlights ongoing questions regarding resistance mechanisms and the clinical feasibility of rechallenging patients with ADC therapies.
Advertisement
Related to this article

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The Pan-Mass Challenge donated a record $80 million to Dana-Farber Cancer Institute to support cancer research, treatment, and patient care.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
5

